Thiabendazole
- Atc Codes:D01AC06#P02CA02
- CAS Codes:148-79-8
- PHARMGKB ID:148-79-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Cyprus: Tiabendazole; Italy: Tiabend.
Latin America
Argentina: Foldan; Brazil: Foldan, Thiabiose, Tiabendazol, Tiadol, Tiaplex.
Drug combinations
Chemistry
Thiabendazole: C~10~H~7~N~3~S. Mw: 201.25. (1) 1H-Benzimidazole, 2-(4-thiazolyl)-; (2) 2-(4-Thiazolyl)benzimidazole. CAS-148-79-8 (1962).
Pharmacologic Category
Antihelmintics. (ATC-Code: D01AC06; P02CA02).
Mechanism of action
Inhibits helminth-specific mitochondrial fumarate reductase.
Therapeutic use
Treatment of strongyloidiasis, cutaneous larva migrans, visceral larva migrans, dracunculiasis, trichinosis, and mixed helminthic infections.
Pregnancy and lactiation implications
Cleft palate and skeletal defects observed in some animal studies. There are no adequate, well-controlled studies in pregnant women. Excretion in breast milk unknown (not recommended in nursing women).
Unlabeled use
Cutaneous larva migrans (topical application).
Contraindications
Hypersensitivity to thiabendazole or any component of the formulation. Not for use as prophylactic treatment of enterobiasis (pinworm) infestation.
Warnings and precautions
May cause CNS depression. Erythema multiforme and Steven’s-Johnson syndrome reported (including fatalities). Ophthalmic changes may occur and persist >1 year. Use with caution in anemia. Not suitable treatment for mixed infections with Ascaris. Use with caution in dehydration, in hepatic impairment (jaundice, cholestasis, parenchymal liver damage occurred), in malnutrition, and in renal impairment. Safety and efficacy limited in children <14 kg (30 lb).